Who Is Buying AbbVie? Hedge Fund Activity in 2026
See which hedge funds are buying, selling, or holding AbbVie (ABBV) based on latest 13F filings. 5 funds buying, institutional value $70.3B.
8 min czytaniaFact-checked against primary sources on · figures re-verified on regulator, issuer or SEC filings — not copied from other sites
Who Is Buying AbbVie? Hedge Fund Activity in 2026
AbbVie, the pharmaceutical powerhouse behind Humira, Skyrizi, and Rinvoq, has been a dividend aristocrat darling for years. At around $208.89 per share, ABBV commands a premium valuation built on its successful transition away from Humira's biosimilar competition. The company's immunology franchise — particularly Skyrizi and Rinvoq — has grown rapidly, but the stock's strong run has now prompted a wave of institutional profit-taking.
The latest 13F filings reveal a striking pattern: 9 out of 18 tracked funds are selling or reducing their AbbVie positions. This is one of the heaviest selling ratios in our entire coverage universe.
Quick Answer
Across the funds we read directly from SEC filings, the largest Abbvie position in the Q2 2026 13Fs (period ending 30 June 2026) is Citadel Advisors at $798M (3,169,783 shares). Measured against the size of each filer's book rather than in dollars, the most concentrated holder is Citadel Advisors, where Abbvie is 0.5% of everything they report. Every figure here is aggregated by CUSIP from the filer's own information table with put/call rows excluded — a 13F lists options beside shares, and adding them together is what produces the inflated stakes quoted elsewhere. Filings lag roughly 45 days: this is positioning as of 30 June 2026, not today, and not investment advice.
AbbVie Institutional Snapshot
| Metric | Value |
|---|---|
| Funds Buying | 5 |
| Funds Selling | 9 |
| Funds Holding | 4 |
| Active Funds Tracked | 18 |
| Share Price | ~$208.89 |
A 5-to-9 buy-sell ratio is a clear bearish tilt. When half the institutional universe is reducing exposure to a single name, it demands serious attention from individual investors. This is one of the most lopsided selling ratios in our current pharmaceutical coverage — and in a stock that has been one of the market's best performers over the past two years.
Savings in one bank, investments in another? See it all in one place — and how many months it could carry you.
See your Freedom Runway — freeWho holds Abbvie, and how much it matters to them
Read from each filer's Q2 2026 information table (period ending 30 June 2026).
| Fund | Position | Shares | Share of the fund's 13F book |
|---|---|---|---|
| Citadel Advisors | $798M | 3,169,783 | 0.5% of $171.84B |
| Millennium Management | $382M | 1,516,475 | 0.3% of $142.92B |
| Bridgewater Associates | $3.0M | 11,775 | 0.0% of $24.38B |
The last column is the one worth reading. A multi-strategy fund reporting a $100B+ book can hold a large dollar amount of Abbvie that means almost nothing to it, while a concentrated fund holding less in dollars may have several percent of its entire book in the name. Rankings by dollar value hide exactly that difference.
Who added and who cut
Comparing each filer's Q1 2026 table with its Q2 2026 one, by share count — the change is what shows conviction, not the size of the position.
| Fund | Q1 2026 shares | Q2 2026 shares | Change |
|---|---|---|---|
| Citadel Advisors | 490,285 | 3,169,783 | +547% |
| Millennium Management | 675,757 | 1,516,475 | +124% |
| Bridgewater Associates | 30,362 | 11,775 | -61% |
A fund absent from this table reported no Abbvie position in either quarter.
Related Articles
- Who Is Buying NVIDIA? Hedge Fund Activity in 2026
- Who Is Buying Apple? Hedge Fund Activity in 2026
- Who Is Buying Tesla? Hedge Fund Activity in 2026
FAQ
What is a 13F filing and how is it used to track AbbVie?
A 13F is a quarterly SEC disclosure where institutional managers with at least $100M in US equity assets list their long equity positions. Investors track 13F filings on AbbVie (ABBV) to see how large funds are positioning around the Humira-to-Skyrizi/Rinvoq transition, with the caveat that the data is lagged and excludes shorts, derivatives, and non-US holdings.
Who are the largest institutional holders of AbbVie?
Index managers such as Vanguard, BlackRock and State Street hold the largest raw positions in almost every large-cap name, because they track the index rather than pick the stock. Among the active filers we read directly from EDGAR, the largest position in the Q2 2026 filings is Citadel Advisors at $798M (3,169,783 shares).
Why are so many hedge funds selling AbbVie?
Across 18 tracked funds, 9 were reducing or exiting their AbbVie positions in the latest snapshot — a notably heavy selling ratio. The most common rationales cited in analyst commentary are valuation after a strong multi-year run, ongoing Humira biosimilar erosion, and concerns about whether Skyrizi and Rinvoq can grow fast enough to maintain the company's premium multiple.
What role do Skyrizi, Rinvoq, and Humira play in the AbbVie thesis?
Humira was historically AbbVie's largest revenue contributor before facing biosimilar competition, and Skyrizi and Rinvoq are the immunology franchises designed to replace and exceed that revenue base. Institutional investors closely track quarterly growth rates of Skyrizi and Rinvoq versus the pace of Humira decline as the core swing factor for the long-term thesis.
What does Renaissance and Balyasny fully exiting AbbVie signal?
Renaissance Technologies and Balyasny Asset Management both completely liquidating their AbbVie positions in the same period is statistically unusual and reinforces a cautious institutional read at recent valuation levels. As always, 13F data describes past positioning rather than a forward forecast, and complete exits from sophisticated funds are one signal among many — not a recommendation to act.